Stay updated on Lirentelimab in Eosinophilic Esophagitis Clinical Trial
Sign up to get notified when there's something new on the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page.

Latest updates to the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page
- Check7 days agoChange DetectedRevision: v3.3.4 was introduced; there are no visible user-facing changes to the Study Details page beyond the version label. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a consolidated Locations section listing all study sites by state and country. Removed the individual state location subsections (e.g., Alabama Locations) and the HHS Vulnerability Disclosure link.SummaryDifference2%

- Check50 days agoChange DetectedThe page revision has been updated to v3.3.2, replacing the previous v3.3.1 entry.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision: v3.3.1 replaces v3.2.0 as an administrative update; no substantive changes to study content, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedRemoved the funding-disclaimer banner about potential delays and outdated information. This is an administrative change that does not alter the study details, enrollment, or outcomes.SummaryDifference0.2%

- Check79 days agoChange DetectedNo additions or deletions were detected on the page; the study details and eligibility criteria remain as published.SummaryDifference0.3%

Stay in the know with updates to Lirentelimab in Eosinophilic Esophagitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page.